Engineered immune cells take aim at stubborn bone cancer
NCT ID NCT05312411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a two-part treatment for osteosarcoma that has come back or not responded to standard care. First, a patient's own T cells are collected and genetically modified to become CAR T cells that can recognize a special flag. Then, after some chemotherapy, the CAR T cells are infused back, followed by doses of a molecule (UB-TT170) that attaches to tumor cells and flags them for destruction by the CAR T cells. The study involves 21 participants and focuses on safety and feasibility over about 8 months of active treatment, with long-term follow-up for 15 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified CAR T cells (antiFL(FITC-E2)) and a targeting molecule (UB-TT170)
- What this could lead to
- If it works, this could point toward a new treatment option for osteosarcoma that doesn't respond to standard therapy.
- What could go wrong
- This is a very early phase 1 trial with only 21 participants, so it's mainly testing safety and feasibility. The treatment may not shrink tumors, and there are risks from chemotherapy and the CAR T cells themselves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill stall advanced sarcomas?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Experimental vaccine fights sarcoma with Patient's own immune cells
- New drug hope for rare sarcomas after chemo fails
- Dietary change explored as cancer support strategy